• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Oric Pharmaceuticals Inc.

    8/14/25 5:34:12 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ORIC alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    Oric Pharmaceuticals, Inc.

    (Name of Issuer)


    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)


    68622P109

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    68622P109


    1Names of Reporting Persons

    VIKING GLOBAL INVESTORS LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    8,729,345.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    8,729,345.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    8,729,345.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    68622P109


    1Names of Reporting Persons

    Viking Global Opportunities Parent GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    8,729,345.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    8,729,345.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    8,729,345.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    68622P109


    1Names of Reporting Persons

    Viking Global Opportunities GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,606,787.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,606,787.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,606,787.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.42 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    68622P109


    1Names of Reporting Persons

    Viking Global Opportunities Portfolio GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,606,787.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,606,787.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,606,787.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.42 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    68622P109


    1Names of Reporting Persons

    Viking Global Opportunities Illiquid Investments Sub-Master LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,606,787.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,606,787.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,606,787.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.42 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    68622P109


    1Names of Reporting Persons

    Viking Global Opportunities Drawdown GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,122,558.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,122,558.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,122,558.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.57 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    68622P109


    1Names of Reporting Persons

    Viking Global Opportunities Drawdown Portfolio GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,122,558.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,122,558.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,122,558.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.57 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    68622P109


    1Names of Reporting Persons

    Viking Global Opportunities Drawdown (Aggregator) LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,122,558.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,122,558.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,122,558.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.57 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    68622P109


    1Names of Reporting Persons

    HALVORSEN OLE ANDREAS
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    NORWAY
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    8,729,345.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    8,729,345.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    8,729,345.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    68622P109


    1Names of Reporting Persons

    Ott David C.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    8,729,345.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    8,729,345.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    8,729,345.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP No.
    68622P109


    1Names of Reporting Persons

    Shabet Rose Sharon
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    8,729,345.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    8,729,345.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    8,729,345.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Oric Pharmaceuticals, Inc.
    (b)Address of issuer's principal executive offices:

    240 E. Grand Ave, 2nd Floor, South San Francisco, California, 94080
    Item 2. 
    (a)Name of person filing:

    Viking Global Investors LP ("VGI"), Viking Global Opportunities Parent GP LLC ("Opportunities Parent"), Viking Global Opportunities GP LLC ("Opportunities GP"), Viking Global Opportunities Portfolio GP LLC ("Opportunities Portfolio GP"), Viking Global Opportunities Illiquid Investments Sub-Master LP ("VGOP"), Viking Global Opportunities Drawdown GP LLC ("VGOD GP"), Viking Global Opportunities Drawdown Portfolio GP LLC ("VGOD Portfolio GP"), Viking Global Opportunities Drawdown (Aggregator) LP ("VGOD"), O. Andreas Halvorsen, David C. Ott and Rose S. Shabet (collectively, the "Reporting Persons")
    (b)Address or principal business office or, if none, residence:

    The business address of each of the Reporting Persons is: 600 Washington Boulevard, Floor 11, Stamford, Connecticut 06901.
    (c)Citizenship:

    VGI is a Delaware limited partnership; Opportunities Parent, Opportunities GP, Opportunities Portfolio GP, VGOD GP and VGOD Portfolio GP are Delaware limited liability companies; VGOP and VGOD are Cayman Islands exempted limited partnerships; O. Andreas Halvorsen is a citizen of Norway; and David C. Ott and Rose S. Shabet are citizens of the United States.
    (d)Title of class of securities:

    Common Stock, $0.0001 par value per share
    (e)CUSIP No.:

    68622P109
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    This Statement on Schedule 13G relates to shares of Common Stock and pre-funded warrants to purchase shares of Common Stock with an exercise price of $0.0001 per share (the "Warrants") held directly by VGOP and VGOD. VGOP directly owns 4,312,800 shares of Common Stock and Warrants with the right to purchase 1,846,182 shares of Common Stock. VGOD directly owns 2,259,900 shares of Common Stock and Warrants with the right to purchase 1,230,788 shares of Common Stock. However, the terms of the Warrants provide that no holder of Warrants shall have the right to exercise any portion of the Warrants to the extent that, after giving effect to such issuance after exercise, such holder of Warrants (together with its affiliates and any member of a Section 13(d) group) would beneficially own more than 9.99% of the number of shares of the Common Stock outstanding immediately following exercise (the "Blocker"). Any holder of Warrants, upon notice to the Issuer, may increase or decrease the Blocker, subject to a maximum of 19.99%, but any such increase or decrease will not be effective until the 61st day after such notice is delivered to the Issuer. Accordingly, the amount of shares of Common Stock reported as beneficially owned by the Reporting Persons set forth herein excludes shares of Common Stock that the Reporting Persons do not currently have the right to purchase upon exercise of the Warrants held directly by VGOP and VGOD due to the Blocker. Under the terms of the Blocker, the Blocker applies to the aggregate number of shares of Common Stock that can be purchased upon exercise of the Warrants held by both VGOP and VGOD, and so has been applied pro rata to the Warrants held directly by each of VGOP and VGOD. VGI: 8,729,345 VGI provides managerial services to VGOP and VGOD. VGI has the authority to dispose of and vote the shares of Common Stock that VGOP and VGOD directly own or have the right to purchase upon exercise of the Warrants. VGI does not directly own any shares of Common Stock or Warrants. Based on Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Act"), VGI may be deemed to beneficially own the shares of Common Stock that VGOP and VGOD directly own or have the right to purchase upon exercise of the Warrants. VGI beneficially owns 8,729,345 shares of Common Stock consisting of (i) 4,312,800 and 2,259,900 shares of Common Stock directly owned by VGOP and VGOD, respectively, and (ii) 1,293,987 and 862,658 shares of Common Stock beneficially owned by VGOP and VGOD, respectively, which VGOP and VGOD have the right to purchase upon exercise of the Warrants, each subject to the Blocker. Opportunities Parent: 8,729,345 Opportunities Parent is the sole member of Opportunities GP, which has the authority to dispose of and vote the shares of Common Stock controlled by Opportunities Portfolio GP (which consists of the shares of Common Stock that VGOP directly owns or has the right to purchase upon exercise of the Warrants), and is the sole member of VGOD GP, which has the authority to dispose of and vote the shares of Common Stock controlled by VGOD Portfolio GP (which consists of the shares of Common Stock that VGOD directly owns or has the right to purchase upon exercise of the Warrants). Opportunities Parent does not directly own any shares of Common Stock or Warrants. Based on Rule 13d-3 under the Act, Opportunities Parent may be deemed to beneficially own the shares of Common Stock that VGOP and VGOD directly own or have the right to purchase upon exercise of the Warrants. Opportunities Parent beneficially owns 8,729,345 shares of Common Stock consisting of (i) 4,312,800 and 2,259,900 shares of Common Stock directly owned by VGOP and VGOD, respectively, and (ii) 1,293,987 and 862,658 shares of Common Stock beneficially owned by VGOP and VGOD, respectively, which VGOP and VGOD have the right to purchase upon exercise of the Warrants, each subject to the Blocker. Opportunities GP: 5,606,787 Opportunities GP serves as the sole member of Opportunities Portfolio GP and has the authority to dispose of and vote the shares of Common Stock controlled by Opportunities Portfolio GP, which consists of the shares of Common Stock that VGOP directly owns or has the right to purchase upon exercise of the Warrants. In addition, Opportunities GP is the general partner of each of Viking Global Opportunities Intermediate LP, Viking Global Opportunities III LP, and Viking Global Opportunities LP. Opportunities GP does not directly own any shares of Common Stock or Warrants. Based on Rule 13d-3 under the Act, Opportunities GP may be deemed to beneficially own the shares of Common Stock that VGOP directly owns or has the right to purchase upon exercise of the Warrants. Opportunities GP beneficially owns 5,606,787 shares of Common Stock consisting of 4,312,800 shares of Common Stock directly owned by VGOP and 1,293,987 shares of Common Stock beneficially owned by VGOP, which VGOP has the right to purchase upon exercise of the Warrants, subject to the Blocker. Opportunities Portfolio GP: 5,606,787 Opportunities Portfolio GP serves as the general partner of VGOP and has the authority to dispose of and vote the shares of Common Stock that VGOP directly owns or has the right to purchase upon exercise of the Warrants. Opportunities Portfolio GP does not directly own any shares of Common Stock or Warrants. Based on Rule 13d-3 under the Act, Opportunities Portfolio GP may be deemed to beneficially own the shares of Common Stock that VGOP directly owns or has the right to purchase upon exercise of the Warrants. Opportunities Portfolio GP beneficially owns 5,606,787 shares of Common Stock consisting of 4,312,800 shares of Common Stock directly owned by VGOP and 1,293,987 shares of Common Stock beneficially owned by VGOP, which VGOP has the right to purchase upon exercise of the Warrants, subject to the Blocker. VGOP: 5,606,787 VGOP has the authority to dispose of and vote the 4,312,800 shares of Common Stock that it owns and the 1,293,987 shares of Common Stock it has the right to purchase upon exercise of the Warrants directly owned by it, subject to the Blocker, which power may be exercised by its general partner, Opportunities Portfolio GP, and by VGI, an affiliate of Opportunities Portfolio GP, which provides managerial services to VGOP. Viking Global Opportunities LP (a Delaware limited partnership) and Viking Global Opportunities III LP (a Cayman Islands exempted limited partnership), through its investment in Viking Global Opportunities Intermediate LP (a Cayman Islands exempted limited partnership), invest substantially all of their assets in Viking Global Opportunities Master LP (a Cayman Islands exempted limited partnership), which in turn invests through VGOP. VGOD GP: 3,122,558 VGOD GP serves as the sole member of VGOD Portfolio GP and has the authority to dispose of and vote the shares of Common Stock controlled by VGOD Portfolio GP, which consists of the shares of Common Stock that VGOD directly owns or has the right to purchase upon exercise of the Warrants. In addition, VGOD GP is the general partner of each of Viking Global Opportunities Drawdown (Internal) LP, Viking Global Opportunities Drawdown (Onshore) LP, and Viking Global Opportunities Drawdown (Offshore) LP. VGOD GP does not directly own any shares of Common Stock or Warrants. Based on Rule 13d-3 under the Act, VGOD GP may be deemed to beneficially own the shares of Common Stock that VGOD directly owns or has the right to purchase upon exercise of the Warrants. VGOD GP beneficially owns 3,122,558 shares of Common Stock consisting of 2,259,900 shares of Common Stock directly owned by VGOD and 862,658 shares of Common Stock beneficially owned by VGOD, which VGOD has the right to purchase upon exercise of the Warrants, subject to the Blocker. VGOD Portfolio GP: 3,122,558 VGOD Portfolio GP serves as the general partner of VGOD and has the authority to dispose of and vote the shares of Common Stock that VGOD directly owns or has the right to purchase upon exercise of the Warrants. VGOD Portfolio GP does not directly own any shares of Common Stock or Warrants. Based on Rule 13d-3 under the Act, VGOD Portfolio GP may be deemed to beneficially own the shares of Common Stock that VGOD directly owns or has the right to purchase upon exercise of the Warrants. VGOD Portfolio GP beneficially owns 3,122,558 shares of Common Stock consisting of 2,259,900 shares of Common Stock directly owned by VGOD and 862,658 shares of Common Stock beneficially owned by VGOD, which VGOD has the right to purchase upon exercise of the Warrants, subject to the Blocker. VGOD: 3,122,558 VGOD has the authority to dispose of and vote the 2,259,900 shares of Common Stock that it directly owns and the 862,658 shares of Common Stock it has the right to purchase upon exercise of the Warrants directly owned by it, subject to the Blocker, which power may be exercised by VGOD Portfolio GP, and by VGI, an affiliate of VGOD Portfolio GP, which provides managerial services to VGOD. Viking Global Opportunities Drawdown (Offshore) LP (a Cayman Islands exempted limited partnership) and Viking Global Opportunities Drawdown (Internal) LP (a Delaware limited partnership), through its investment in Viking Global Opportunities Drawdown (Onshore) LP (a Delaware limited partnership), invest substantially all of their assets in VGOD. O. Andreas Halvorsen, David C. Ott and Rose S. Shabet: 8,729,345 Mr. Halvorsen, Mr. Ott and Ms. Shabet, as Executive Committee Members of Viking Global Partners LLC (general partner of VGI) and Opportunities Parent, have shared authority to dispose of and vote the shares of Common Stock beneficially owned by VGI and Opportunities Parent. None of Mr. Halvorsen, Mr. Ott and Ms. Shabet directly owns any shares of Common Stock or Warrants. Based on Rule 13d-3 under the Act, each may be deemed to beneficially own the shares of Common Stock that VGOP and VGOD directly own or have the right to purchase upon exercise of the Warrants. Each of Mr. Halvorsen, Mr. Ott and Ms. Shabet beneficially owns 8,729,345 shares of Common Stock consisting of (i) 4,312,800 and 2,259,900 shares of Common Stock directly owned by VGOP and VGOD, respectively, and (ii) 1,293,987 and 862,658 shares of Common Stock beneficially owned by VGOP and VGOD, respectively, which VGOP and VGOD have the right to purchase upon exercise of the Warrants, each subject to the Blocker.
    (b)Percent of class:

    The percentages set forth herein are based on (i) 85,224,191 shares of Common Stock outstanding as of May 29, 2025, as reported in the Issuer's prospectus on Form 424B3, filed with the Securities and Exchange Commission (the "Commission") on June 24, 2025, and (ii) 2,156,645 shares of Common Stock that the Reporting Persons currently have the right to purchase upon exercise of the Warrants, subject to the Blocker. VGI: 9.99% Opportunities Parent: 9.99% Opportunities GP: 6.42% Opportunities Portfolio GP: 6.42% VGOP: 6.42% VGOD GP: 3.57% VGOD Portfolio GP: 3.57% VGOD: 3.57% O. Andreas Halvorsen, David C. Ott and Rose S. Shabet: 9.99%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    VGI: 0 Opportunities Parent: 0 Opportunities GP: 0 Opportunities Portfolio GP: 0 VGOP: 0 VGOD GP: 0 VGOD Portfolio GP: 0 VGOD: 0 O. Andreas Halvorsen, David C. Ott and Rose S. Shabet: 0

     (ii) Shared power to vote or to direct the vote:

    VGI: 8,729,345 Opportunities Parent: 8,729,345 Opportunities GP: 5,606,787 Opportunities Portfolio GP: 5,606,787 VGOP: 5,606,787 VGOD GP: 3,122,558 VGOD Portfolio GP: 3,122,558 VGOD: 3,122,558 O. Andreas Halvorsen, David C. Ott and Rose S. Shabet: 8,729,345

     (iii) Sole power to dispose or to direct the disposition of:

    VGI: 0 Opportunities Parent: 0 Opportunities GP: 0 Opportunities Portfolio GP: 0 VGOP: 0 VGOD GP: 0 VGOD Portfolio GP: 0 VGOD: 0 O. Andreas Halvorsen, David C. Ott and Rose S. Shabet: 0

     (iv) Shared power to dispose or to direct the disposition of:

    VGI: 8,729,345 Opportunities Parent: 8,729,345 Opportunities GP: 5,606,787 Opportunities Portfolio GP: 5,606,787 VGOP: 5,606,787 VGOD GP: 3,122,558 VGOD Portfolio GP: 3,122,558 VGOD: 3,122,558 O. Andreas Halvorsen, David C. Ott and Rose S. Shabet: 8,729,345

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The response to Item 4 is incorporated by reference herein.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    VIKING GLOBAL INVESTORS LP
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of VIKING GLOBAL INVESTORS LP (1)(2)(3)
    Date:08/14/2025
     
    Viking Global Opportunities Parent GP LLC
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Parent GP LLC (1)(2)(3)
    Date:08/14/2025
     
    Viking Global Opportunities GP LLC
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities GP LLC (1)(2)(3)
    Date:08/14/2025
     
    Viking Global Opportunities Portfolio GP LLC
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Portfolio GP LLC (1)(2)(3)
    Date:08/14/2025
     
    Viking Global Opportunities Illiquid Investments Sub-Master LP
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Illiquid Investments Sub-Master LP (1)(2)(3)
    Date:08/14/2025
     
    Viking Global Opportunities Drawdown GP LLC
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Drawdown GP LLC (1)(2)(3)
    Date:08/14/2025
     
    Viking Global Opportunities Drawdown Portfolio GP LLC
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Drawdown Portfolio GP LLC (1)(2)(3)
    Date:08/14/2025
     
    Viking Global Opportunities Drawdown (Aggregator) LP
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Drawdown (Aggregator) LP (1)(2)(3)
    Date:08/14/2025
     
    HALVORSEN OLE ANDREAS
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of O. Andreas Halvorsen (1)
    Date:08/14/2025
     
    Ott David C.
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of David C. Ott (2)
    Date:08/14/2025
     
    Shabet Rose Sharon
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Rose S. Shabet (3)
    Date:08/14/2025

    Comments accompanying signature:  (1) Scott M. Hendler is signing on behalf of O. Andreas Halvorsen, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, VIKING GLOBAL OPPORTUNITIES DRAWDOWN GP LLC, VIKING GLOBAL OPPORTUNITIES DRAWDOWN PORTFOLIO GP LLC and VIKING GLOBAL OPPORTUNITIES DRAWDOWN (AGGREGATOR) LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737). (2) Scott M. Hendler is signing on behalf of David C. Ott, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, VIKING GLOBAL OPPORTUNITIES DRAWDOWN GP LLC, VIKING GLOBAL OPPORTUNITIES DRAWDOWN PORTFOLIO GP LLC and VIKING GLOBAL OPPORTUNITIES DRAWDOWN (AGGREGATOR) LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737). (3) Scott M. Hendler is signing on behalf of Rose S. Shabet, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, VIKING GLOBAL OPPORTUNITIES DRAWDOWN GP LLC, VIKING GLOBAL OPPORTUNITIES DRAWDOWN PORTFOLIO GP LLC and VIKING GLOBAL OPPORTUNITIES DRAWDOWN (AGGREGATOR) LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737).
    Exhibit Information

    EXHIBIT A - JOINT FILING AGREEMENT

    Get the next $ORIC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ORIC

    DatePrice TargetRatingAnalyst
    7/8/2025$15.00Buy
    Ladenburg Thalmann
    10/31/2024$20.00Overweight
    Wells Fargo
    9/6/2024$20.00Buy
    Stifel
    2/23/2024Overweight
    Cantor Fitzgerald
    9/22/2023$8.00Outperform
    Wedbush
    3/23/2023$16.00Neutral → Buy
    H.C. Wainwright
    3/21/2023$15.00Neutral → Buy
    Guggenheim
    3/16/2023$14.00Perform → Outperform
    Oppenheimer
    More analyst ratings

    $ORIC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ORIC® Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer

    SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of Kevin Brodbeck, PhD, to the newly established role of Chief Technical Officer (CTO). Dr. Brodbeck brings more than 25 years of experience leading technical operations, quality assurance, chemistry, manufacturing and controls (CMC), and regulatory activities across a wide range of pharmaceutical products at all stages of development and commercialization. The creation of the CTO role and Dr. Brodbeck's appointment reflect t

    8/18/25 4:05:00 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ORIC® Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Updates

    Reported potentially best-in-class clinical efficacy and safety data from ongoing Phase 1b trial of ORIC-944 in combination with AR inhibitors for the treatment of patients with mCRPC Strengthened cash position with $244 million gross proceeds from top-tier healthcare specialist investors across $125 million private placement financing and $119 million ATM issuances; Following recent financing activity, ORIC concludes anticipated ATM facility usage In anticipation of potential initiation of registrational trials in 2026 for ORIC-944 and ORIC-114 (enozertinib), the company has revised its operating plan to substantially reduce investment in discovery research Under the revised operating

    8/12/25 4:05:00 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on August 1, 2025 (the "Grant Date"), ORIC granted a total of 35,000 non-qualified stock options and 5,800 restricted stock units to two new non-executive employees who began their employment with ORIC in July 2025. These inducement grants were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to recipient's continued employment or service through each applicable vesting date. The stock o

    8/1/25 4:30:00 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORIC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director You Angie bought $262,899 worth of shares (28,000 units at $9.39) (SEC Form 4)

    4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)

    6/23/25 8:05:17 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORIC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ladenburg Thalmann initiated coverage on ORIC Pharmaceuticals with a new price target

    Ladenburg Thalmann initiated coverage of ORIC Pharmaceuticals with a rating of Buy and set a new price target of $15.00

    7/8/25 8:35:06 AM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on ORIC Pharmaceuticals with a new price target

    Wells Fargo initiated coverage of ORIC Pharmaceuticals with a rating of Overweight and set a new price target of $20.00

    10/31/24 6:33:23 AM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel initiated coverage on ORIC Pharmaceuticals with a new price target

    Stifel initiated coverage of ORIC Pharmaceuticals with a rating of Buy and set a new price target of $20.00

    9/6/24 7:48:52 AM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORIC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Piscitelli Dominic sold $200,972 worth of shares (20,000 units at $10.05), decreasing direct ownership by 29% to 48,317 units (SEC Form 4)

    4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)

    7/2/25 4:07:16 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Piscitelli Dominic sold $351,384 worth of shares (33,500 units at $10.49), decreasing direct ownership by 33% to 68,317 units (SEC Form 4)

    4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)

    6/24/25 6:33:12 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director You Angie bought $262,899 worth of shares (28,000 units at $9.39) (SEC Form 4)

    4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)

    6/23/25 8:05:17 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORIC
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Oric Pharmaceuticals Inc.

    SCHEDULE 13G/A - Oric Pharmaceuticals, Inc. (0001796280) (Subject)

    8/14/25 5:34:12 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Oric Pharmaceuticals Inc.

    10-Q - Oric Pharmaceuticals, Inc. (0001796280) (Filer)

    8/12/25 4:20:22 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oric Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities

    8-K - Oric Pharmaceuticals, Inc. (0001796280) (Filer)

    8/12/25 4:10:30 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORIC
    Leadership Updates

    Live Leadership Updates

    View All

    ORIC® Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer

    SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of Kevin Brodbeck, PhD, to the newly established role of Chief Technical Officer (CTO). Dr. Brodbeck brings more than 25 years of experience leading technical operations, quality assurance, chemistry, manufacturing and controls (CMC), and regulatory activities across a wide range of pharmaceutical products at all stages of development and commercialization. The creation of the CTO role and Dr. Brodbeck's appointment reflect t

    8/18/25 4:05:00 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates

    Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with androgen receptor inhibitors in patients with mCRPC Entered into clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC-114 in combination with subcutaneous amivantamab for the first-line treatment of NSCLC patients with EGFR exon 20 insertion mutations Expects to report seven data readouts across ORIC-114 and ORIC-944 clinical programs over the next 18 months, with potential initiation of registrational trials in 2H25 and early 2026 Cash and investments of $256 million expected

    2/18/25 4:05:00 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ORIC® Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones

    Announces encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with apalutamide in patients with mCRPC Entered into clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC-114 in combination with subcutaneous amivantamab for the first-line treatment of NSCLC patients with EGFR exon 20 insertion mutations Expects to report seven data readouts across ORIC-114 and ORIC-944 clinical programs over the next 18 months, with potential initiation of registrational trials in 2H25 and early 2026 Cash and investments expected to fund operating plan into late 2026 SOUTH SAN FRANCISCO and SAN DIEGO, J

    1/13/25 8:05:00 AM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORIC
    Financials

    Live finance-specific insights

    View All

    ORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC

    Broad and deep PSA responses achieved, with 59% PSA50 response rate (confirmed rate of 47%, and one additional response pending confirmation) and 24% PSA90 response rate (all confirmed) in patients with mCRPC       PSA responses were observed across all ORIC-944 dose levels and at comparable rates in combination with apalutamide and with darolutamide; majority of patients are still ongoing with multiple patients approaching one year or more Both combination regimens demonstrated a safety profile compatible with long term dosing, with the vast majority of adverse events Grade 1 or 2 Announced concurrent $125 million financing, which extends cash runway into 2H 2027 and through anticipated

    5/28/25 4:05:00 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ORIC® Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPC

    SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that the company will present initial data from the Phase 1b trial of ORIC-944 in combination with androgen receptor inhibitors in patients with metastatic castration resistant prostate cancer (mCRPC) in a conference call and webcast on Wednesday, May 28, 2025, at 4:30 p.m. ET. To join the conference call via phone and participate in the live Q&A session, please pre-register online here to receive a telephone number and unique passcode req

    5/27/25 8:00:00 AM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development

    Preliminary evidence of clinical antimyeloma activity, including reduction in paraprotein, demonstrated in multiple patients Clean safety profile with only Grade 1 and 2 treatment related adverse events and no dose limiting toxicities or dose reductions Clinical activity, safety profile, and dose-dependent increases in immune cell activation support potential for combination studies with other multiple myeloma agents, including BCMA- and CD38-directed therapies Company to pursue strategic partnership for combination studies, resulting in extension of cash runway into 2026 Company to host conference call and webcast today at 4:30 pm ET SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 11

    12/11/23 12:00:00 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORIC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Oric Pharmaceuticals Inc.

    SC 13G/A - Oric Pharmaceuticals, Inc. (0001796280) (Subject)

    11/14/24 5:54:12 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Oric Pharmaceuticals Inc.

    SC 13G/A - Oric Pharmaceuticals, Inc. (0001796280) (Subject)

    11/14/24 5:47:31 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Oric Pharmaceuticals Inc.

    SC 13G/A - Oric Pharmaceuticals, Inc. (0001796280) (Subject)

    11/14/24 5:14:58 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care